Patents Assigned to Lycera Corporation
  • Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 10745364
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 18, 2020
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10611740
    Abstract: The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 7, 2020
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
    Patent number: 10556898
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 11, 2020
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Fernando Padilla, Donald J. Skalitzky, Peter L. Toogood, Chad A. VanHuis
  • Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
    Patent number: 10532088
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 14, 2020
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10442798
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 15, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10421751
    Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • N-substituted pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 10392350
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: August 27, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 10377768
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 13, 2019
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10364237
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 10221146
    Abstract: The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 5, 2019
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10208061
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: February 19, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Benzenesulfonamido and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10189777
    Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: January 29, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor, Chad A. Van Huis
  • Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
    Patent number: 10112935
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 30, 2018
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Fernando Padilla, Peter L. Toogood, Shoujun Chen
  • Trifluoromethyl pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 10085972
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9932313
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 3, 2018
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Indazole guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9920012
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 20, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • N-substituted pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9914706
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: March 13, 2018
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor
  • Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 9896441
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: February 20, 2018
    Assignee: LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Alkylpyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9815791
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: November 14, 2017
    Assignee: LYCERA CORPORATION
    Inventors: Donald J. Skalitzky, Chad A. VanHuis
  • Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 9809561
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 7, 2017
    Assignees: MERCK SHARP & DOHME CORP., LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov